Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump’s statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
Will RBI rate hikes intensify selloff in bank stocks? Analysts explain why fears may be overdone
Bank shares have endured steep declines as investors brace for imminent interest rate hikes from the RBI. Some analysts suggest that the recent selloff may
September 30, 2026